Literature DB >> 20715107

Specific infiltration of langerin-positive dendritic cells in EBV-infected tonsil, Hodgkin lymphoma and nasopharyngeal carcinoma.

Paulo Henrique Braz-Silva1, Sébastien Vitale, Catherine Butori, Nicolas Guevara, José Santini, Marina Magalhães, Paul Hofman, Alain Doglio.   

Abstract

We report here the existence of a novel subset of langerin (CD207)-positive, immature dendritic cells (DCs) (CD83(neg) ) abundantly infiltrating Epstein Barr virus (EBV)-infected areas in tonsil, Hodgkin lymphoma and nasopharyngeal carcinoma. These CD207(+) DCs differ from conventional epidermal Langerhans cells in their lack of CD1a and CCR6 and their unusual tissue localization. CD207(+) DC infiltration strongly correlates with EBV infection because it was neither detected in EBV negative specimens nor in tissues infected with other human viruses. These immature DCs might represent good candidates for induction of the EBV-specific immune response.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20715107     DOI: 10.1002/ijc.25597

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Dendritic cell subpopulations in nasopharyngeal cancer.

Authors:  Johan S Nilsson; Milad Abolhalaj; Kristina Lundberg; Malin Lindstedt; Lennart Greiff
Journal:  Oncol Lett       Date:  2018-12-14       Impact factor: 2.967

2.  Paucilymphoid non-keratinizing nasopharyngeal carcinoma with prominent stromal desmoplasia--an unusual case reported with brief comments on uncommon histological variants.

Authors:  Fredrik Petersson; Kwok Seng Loh; Diana Lim
Journal:  Int J Clin Exp Pathol       Date:  2011-04-03

3.  CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells.

Authors:  Hiroyuki Abe; Ruri Saito; Takashi Ichimura; Akiko Iwasaki; Sho Yamazawa; Aya Shinozaki-Ushiku; Teppei Morikawa; Tetsuo Ushiku; Hiroharu Yamashita; Yasuyuki Seto; Masashi Fukayama
Journal:  Virchows Arch       Date:  2018-03-13       Impact factor: 4.064

Review 4.  Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.

Authors:  Xueyi Zheng; Yuhua Huang; Kai Li; Rongzhen Luo; Muyan Cai; Jingping Yun
Journal:  Viruses       Date:  2022-05-10       Impact factor: 5.818

Review 5.  Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy.

Authors:  Athanasios Blanas; Neha M Sahasrabudhe; Ernesto Rodríguez; Yvette van Kooyk; Sandra J van Vliet
Journal:  Front Oncol       Date:  2018-02-23       Impact factor: 6.244

Review 6.  The Microenvironment in Epstein-Barr Virus-Associated Malignancies.

Authors:  Geok Wee Tan; Lydia Visser; Lu Ping Tan; Anke van den Berg; Arjan Diepstra
Journal:  Pathogens       Date:  2018-04-13

7.  Epstein-Barr virus encoded dUTPase containing exosomes modulate innate and adaptive immune responses in human dendritic cells and peripheral blood mononuclear cells.

Authors:  Maria Eugenia Ariza; Pierre Rivailler; Ronald Glaser; Min Chen; Marshall V Williams
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

8.  CD1c-Related DCs that Express CD207/Langerin, but Are Distinguishable from Langerhans Cells, Are Consistently Present in Human Tonsils.

Authors:  Anne De Monte; Charles-Vivien Olivieri; Sébastien Vitale; Sonanda Bailleux; Laurent Castillo; Valérie Giordanengo; Janet L Maryanski; Elodie Segura; Alain Doglio
Journal:  Front Immunol       Date:  2016-05-25       Impact factor: 7.561

9.  CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma.

Authors:  Grzegorz Dyduch; Katarzyna E Tyrak; Anna Glajcar; Joanna Szpor; Krzysztof Okoń
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

10.  Immune Phenotypes of Nasopharyngeal Cancer.

Authors:  Johan S Nilsson; Aastha Sobti; Sabine Swoboda; Jonas S Erjefält; Ola Forslund; Malin Lindstedt; Lennart Greiff
Journal:  Cancers (Basel)       Date:  2020-11-18       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.